(Q46116294)

English

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

scientific article published on 20 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Valtteri Kaasinen

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

author name string

Mikko Kuoppamäki

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Kirsi Korpela

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Reijo Marttila

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Päivi Hartikainen

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Jukka Lyytinen

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Seppo Kaakkola

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Jutta Hänninen

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Eliisa Löyttyniemi

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Marita Kailajärvi

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Päivi Ruokoniemi

11

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

Juha Ellmén

12

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

65

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

443-455

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

https://scigraph.springernature.com/pub.10.1007/s00228-009-0622-y

0 references

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-009-0622-Y

21 January 2018

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00228-009-0622-Y

21 January 2018

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-009-0622-Y

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The analysis of the two-period repeated measurements crossover design with application to clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levodopa infusion therapy in Parkinson disease: state of the art in 2004.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19229530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-009-0622-Y

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19229530

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46116294&oldid=2143344930"